Geeza, a bit aggressive there Milly. Are you sure you are a non...

Geeza, a bit aggressive there Milly. Are you sure you are a non holder? Weird to be so defensive when you have no skin in the game.

4 trials hitting arms this year. All novel drugs against unmet needs. One trial financed by other parties. For a market circa of $20 million. And thats aud not usd. And three quarters of that market cap is money in the bank. Admittedly, CarT is expensive, so that will be burned due trials. But it is enough to drive the company through some major pivot piunts with four trials hitting arms.

Normal life expectancy for GBM is 12 to 18 months. And thats from diagnosis. CHM started treatment as a 4th line of treatment, with over 76% of of treated cohort showing survival for a statistical amount longer than that number. Thats more than enough for an accelerated approval pathway. Thete is no effective SOC.

Maybe you can find a more bang for ya buck biotech on the ASX (and many are cheap now) but I haven't.

Couldn't understand the last bit of your post. So hope you are ok.